Integra LifeSciences：强劲的2026年第二季度业绩支持复苏论点（纳斯达克：IART）
· seekingalpha.com
Integra LifeSciences Holdings 是一个扭亏为盈的故事，在2026年第二季度盈利超预期和利润率扩张后维持买入评级。点击了解更多关于IART的信息。
I last wrote about Integra LifeSciences Holdings Corporation ( IART ) on June 22 with a BUY rating, where my thesis was that the company is a turnaround story f...